Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HNF4A | P41235 | 1/20 | 0.63 |
| ▸ | APP | P05067 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 3/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | CA9 | Q16790 | 3/20 | 0.46 |
| ▸ | ASIC3 | Q9UHC3 | 2/20 | 0.44 |
| ▸ | GRM5 | P41594 | 2/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.44 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.43 |
| ▸ | IDH1 | O75874 | 1/20 | 0.42 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4267311 | 1.00 | HNF4A (0.63) | HNF4AAPPMAPTALOX5CA12 | |
| SCHEMBL18130059 | 0.88 | APP (0.48) | HNF4AAPPMAPTALOX5CA12 | |
| SCHEMBL30940362 | 0.84 | APP (0.54) | HNF4AAPPMAPTALOX5CA12 | |
| SCHEMBL18130066 | 0.84 | APP (0.54) | HNF4AAPPMAPTALOX5CA12 | |
| SCHEMBL18130072 | 0.83 | CA12 (0.59) | HNF4AAPPCA12CA1CA2 | |
| SCHEMBL29640419 | 0.83 | CA12 (0.59) | HNF4AAPPCA12CA1CA2 | |
| SCHEMBL28739815 | 0.83 | HNF4A (0.55) | HNF4AAPPMAPTCA12CA1 | |
| SCHEMBL10241970 | 0.81 | HNF4A (0.58) | HNF4AAPPMAPTCA12CA1 | |
| SCHEMBL11193377 | 0.81 | HNF4A (0.58) | HNF4AAPPMAPTCA12CA1 | |
| SCHEMBL4438282 | 0.81 | MAPT (0.54) | HNF4AAPPMAPTCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3280402-B1 | TOLAN COMPOUNDS FOR PROMOTING WOUND HEALING | BIOMENDICS LLC (US) | 2024-06-05 | — | — | EP | disclosed |
| US-11351126-B2 | Substituted tolans for the modulation of microbial colonization | BioMendics, LLC (US) | 2022-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11351126-B2 | Substituted tolans for the modulation of microbial colonization | LMAN1, DPM1, DSTN | HNF4A 4321/4885APP 3466/4885MAPT 1894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.